Granisetron Hydrochloride solution for injection USP 1 mg/1ml; 3mg/3ml; 4mg/4ml in Pre-filled Syringe Taj Pharma

  1. Name of the medicinal product

Granisetron Hydrochloride solution for injection USP 1 mg/1ml; 3mg/3ml; 4mg/4ml in Pre-filled Syringe Taj Pharma

  1. Qualitative and quantitative composition

The active substance is granisetron hydrochloride.

1ml solution for injection contains
1.12 mg granisetron hydrochloride equivalent to 1 mg granisetron.

3ml solution for injection contains
3.36 mg granisetron hydrochloride equivalent to 3 mg granisetron.

4ml solution for injection contains
4.48 mg granisetron hydrochloride equivalent to 4 mg granisetron.

This medicine contains Sodium

For the full list of excipients, see section 6.1.

  1. Pharmaceutical form

Concentrate for solution for injection or infusion

The solution for injection is a clear, colourless liquid.

  1. Clinical particulars

4.1 Therapeutic indications

Granisetron is indicated in adults for the prevention and treatment of

– acute nausea and vomiting associated with chemotherapy and radiotherapy.

– post-operative nausea and vomiting.

Granisetron is indicated for the prevention of delayed nausea and vomiting associated with chemotherapy and radiotherapy.

Granisetron is indicated in children aged 2 years and above for the prevention and treatment of acute nausea and vomiting associated with chemotherapy.

4.2 Posology and method of administration

Posology

Chemo- and radiotherapy-induced nausea and vomiting (CINV and RINV)

Prevention (acute and delayed nausea and vomiting)

A dose of 1 – 3 mg (10 – 40 µg/kg) of Granisetron should be administered either as a slow intravenous injection or as a diluted intravenous infusion 5 minutes prior to the start of chemotherapy or radiotherapy. The solution should be diluted to 5 ml per mg.

Treatment (acute nausea and vomiting)

A dose of 1 – 3 mg (10 – 40 µg/kg) of Granisetron should be administered either as a slow intravenous injection or as a diluted intravenous infusion and administered over 5 minutes. The solution should be diluted to 5 ml per mg. Further maintenance doses of Granisetron may be administered at least 10 minutes apart. The maximum dose to be administered over 24 hours should not exceed 9 mg.

Combination with adrenocortical steroid

The efficacy of parenteral granisetron may be enhanced by an additional intravenous dose of an adrenocortical steroid e.g. by 8 – 20 mg dexamethasone administered before the start of the cytostatic therapy or by 250 mg methyl-prednisolone administered prior to the start and shortly after the end of the chemotherapy.

Paediatric population

The safety and efficacy of granisetron in children aged 2 years and above has been well established for the prevention and treatment (control) of acute nausea and vomiting associated with chemotherapy. A dose of 10 – 40 µg/kg body weight (up to 3 mg) should be administered as an IV infusion, diluted in 10 – 30 ml infusion fluid and administered over 5 minutes prior to the start of chemotherapy. One additional dose may be administered within a 24 hour-period if required. This additional dose should not be administered until at least 10 minutes after the initial infusion.

Post-operative nausea and vomiting (PONV)

A dose of 1 mg (10 µg/kg) of Granisetron should be administered by slow intravenous injection. The maximum dose of Granisetron to be administered over 24 hours should not exceed 3 mg.

For the prevention of PONV, administration should be completed prior to induction of anaesthesia.

Paediatric population

Currently available data are described in section 5.1, but no recommendation on a posology can be made. There is insufficient clinical evidence to recommend administration of the solution for injection to children in prevention and treatment of post-operative nausea and vomiting.

Special populations

Elderly and renal impairment

There are no special precautions required for its use in either elderly patients or those patients with renal or hepatic impairment.

Hepatic impairment

There is no evidence to date for an increased incidence of adverse events in patients with hepatic disorders. On the basis of its kinetics, whilst no dosage adjustment is necessary, granisetron should be used with a certain amount of caution in this patient group (see section 5.2).

Method of administration

Administration may be as either a slow intravenous injection (over 30 seconds) or as an intravenous infusion diluted in 20 – 50 ml infusion fluid and administered over 5 minutes.

For instructions on dilution of the medicinal product before administration, see section 6.6.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use

As granisetron may reduce lower bowel motility, patients with signs of sub-acute intestinal obstruction should be monitored following its administration.

As for other 5-HT3 antagonists, ECG changes including QT interval prolongation have been reported with granisetron. In patients with pre-existing arrhythmias or cardiac conduction disorders this might lead to clinical consequences. Therefore caution should be exercised in patients with cardiac co-morbidities, on cardiotoxic chemotherapy and/or with concomitant electrolyte abnormalities (see section 4.5).

Cross-sensitivity between 5-HT3 antagonists (e.g. dolasetron, ondansetron) has been reported.

Serotonin syndrome

There have been reports of serotonin syndrome with the use of 5-HT3 antagonists either alone, but mostly in combination with other serotonergic drugs (including selective serotonin reuptake inhibitors (SSRIs), and serotonin noradrenaline reuptake inhibitors (SNRIs). Appropriate observation of patients for serotonin syndrome-like symptoms is advised.

This medicine contains:

  • a maximum of 27.7 mg (or 1.2 mmol) sodium per 1 ml Pre-filled Syringes, equivalent to 1.4% of the WHO recommended maximum daily intake of 2 g sodium for an adult.
  • a maximum of 83.1 mg (or 3.6 mmol) sodium per 3 ml Pre-filled Syringes, equivalent to 4.2% of the WHO recommended maximum daily intake of 2 g sodium for an adult.

4.5 Interaction with other medicinal products and other forms of interaction

As for other 5-HT3 antagonists, cases of ECG modifications including QT prolongation have been reported with granisetron. In patients concurrently treated with medicinal products known to prolong QT interval and/or which are arrhythmogenic, this may lead to clinical consequences (see section 4.4).

In humans, hepatic enzyme induction with phenobarbital resulted in an increase in total plasma clearance of granisetron of approximately 25%.

In studies in healthy subjects, no evidence of any interaction has been indicated between granisetron and benzodiazepines (lorazepam), neuroleptics (haloperidol) or anti-ulcer medicinal products (cimetidine). Additionally, granisetron has not shown any apparent medicinal product interaction with emetogenic cancer chemotherapies.

No specific interaction studies have been conducted in anaesthetised patients.

Serotonergic medicinal products (e.g. SSRIs and SNRIs)

There have been reports of serotonin syndrome following concomitant use of 5-HT3 antagonists and other serotonergic medicinal products (including SSRIs and SNRIs) (see section 4.4).

4.6 Fertility, pregnancy and lactation

Pregnancy

There is limited amount of data from the use of granisetron in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). As a precautionary measure, it is preferable to avoid the use of granisetron during pregnancy.

Breastfeeding

It is unknown whether granisetron or its metabolites are excreted in human milk. As a precautionary measure, breastfeeding should not be advised during treatment with Granisetron.

Fertility

In rats, granisetron had no harmful effects on reproductive performance or fertility

4.7 Effects on ability to drive and use machines

Granisetron has no or negligible influence on the ability to drive or to use machines.

4.8 Undesirable effects

Summary of the safety profile

The most frequently reported adverse reactions for granisetron are headache and constipation which may be transient. ECG changes including QT prolongation have been reported with granisetron (see sections 4.4 and 4.5).

Tabulated summary of adverse reactions

The following table of listed adverse reactions is derived from clinical trials and post-marketing data associated with granisetron and other 5-HTantagonists.

Frequency categories are as follows:

Very common: (≥1/10)

Common (≥1/100 to <1/10)

Uncommon (≥1/1,000 to <1/100)

Rare (≥1/10,000 to <1/1,000)

Very rare (<1/10,000)

System organ classFrequency
Immune system disordersUncommon

Hypersensitivity reactions e.g. anaphylaxis, urticaria

Psychiatric disordersCommon

Insomnia

Nervous system disordersVery Common

Headache

Uncommon

Extrapyramidal reactions, Serotonin syndrome

Cardiac disordersUncommon

QT interval prolonged

Gastrointestinal disordersVery common

Constipation

Common

Diarrhoea

Hepatobiliary disordersCommon

Transaminases increased*

Skin and subcutaneous tissue disordersUncommon

Rash

*Occurred at a similar frequency in patients receiving comparator therapy

Description of selected adverse reactions

As for other 5-HT3 antagonists, ECG changes including QT prolongation have been reported with granisetron (see sections 4.4 and 4.5).

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse.

4.9 Overdose

There is no specific antidote for granisetron. In the case of overdose with the injection or infusion, symptomatic treatment should be given. Doses of up to 38.5 mg of granisetron as a single injection have been reported, with symptoms of mild headache but no other reported sequelae.

  1. Pharmacological properties

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antiemetics and antinauseants, Serotonin (5-HT3) antagonists.

Neurological mechanisms, serotonin-mediated nausea and vomiting

Serotonin is the main neurotransmitter responsible for emesis after chemo- or radiotherapy. The 5-HT3 receptors are located in three sites: vagal nerve terminals in the gastrointestinal tract and chemoreceptor trigger zones located in the area postrema and the nucleus tractus solidarius of the vomiting centre in the brainstem. The chemoreceptor trigger zones are located at the caudal end of the fourth ventricle (area postrema). This structure lacks an effective blood-brain barrier, and will detect emetic agents in both the systemic circulation and the cerebrospinal fluid. The vomiting centre is located in the brainstem medullary structures. It receives major inputs from the chemoreceptor trigger zones, and a vagal and sympathetic input from the gut.

Following exposure to radiation or cytotoxic substances, serotonin (5-HT) is released from enterochromaffine cells in the small intestinal mucosa, which are adjacent to the vagal afferent neurons on which 5-HT3 receptors are located. The released serotonin activates vagal neurons via the 5-HT3 receptors which lead ultimately to a severe emetic response mediated via the chemoreceptor trigger zone within the area postrema.

Mechanism of action

Granisetron is a potent antiemetic and highly selective antagonist of 5-hydroxytryptamine (5 HT3) receptors. Radioligand binding studies have demonstrated that granisetron has negligible affinity for other receptor types including 5-HT and dopamine D2 binding sites.

Chemotherapy- and radiotherapy-induced nausea and vomiting

Granisetron administered intravenously has been shown to prevent nausea and vomiting associated with cancer chemotherapy in adults and children 2 – 16 years of age.

Post-operative nausea and vomiting

Granisetron administered intravenously has been shown to be effective for prevention and treatment of post-operative nausea and vomiting in adults.

Pharmacological properties of granisetron

Interaction with neurotropic and other active substances through its activity on P 450-cytochrome has been reported (see section 4.5).

In vitro studies have shown that the cytochrome P450 subfamily 3A4 (involved in the metabolism of some of the main narcotic agents) is not modified by granisetron. Although ketoconazole was shown to inhibit the ring oxidation of granisetron in vitro, this action is not considered clinically relevant.

Although QT prolongation has been observed with 5-HT3 receptors antagonists (see section 4.4), this effect is of such occurrence and magnitude that it does not bear clinical significance in normal subjects. Nonetheless it is advisable to monitor both ECG and clinical abnormalities when treating patients concurrently with medicinal products known to prolong the QT (see section 4.5).

Paediatric population

Clinical application of granisetron was reported by Candiotti et al. A prospective, multicentre, randomized, double-blind, parallel-group study evaluated 157 children 2 to 16 years of age undergoing elective surgery. Total control of post-operative nausea and vomiting during the first 2 hours after surgery was observed in most patients.

5.2 Pharmacokinetic properties

Pharmacokinetics of the oral administration is linear up to 2.5-fold of the recommended dose in adults. It is clear from the extensive dose-finding programme that the antiemetic efficacy is not unequivocally correlated with either administered doses or plasma concentrations of granisetron.

A fourfold increase in the initial prophylactic dose of granisetron made no difference in terms of either the proportion of patient responding to treatment or in the duration of symptom control.

Distribution

Granisetron is extensively distributed, with a mean volume of distribution of approximately 3 l/kg. Plasma protein binding is approximately 65%.

Biotransformation

Granisetron is metabolized primarily in the liver by oxidation followed by conjugation. The major compounds are 7-OH-granisetron and its sulphate and glycuronide conjugates. Although antiemetic properties have been observed for 7-OH-granisetron and indazoline N-desmethyl granisetron, it is unlikely that these contribute significantly to the pharmacological activity of granisetron in man. In vitro liver microsomal studies show that granisetron’s major route of metabolism is inhibited by ketoconazole, suggestive of metabolism mediated by the cytochrome P 450 3A subfamily.

Elimination

Clearance is predominantly by hepatic metabolism. Urinary excretion of unchanged granisetron averages 12% of dose while that of metabolites amounts to about 47% of dose. The remainder is excreted in faeces as metabolites. Mean plasma half-life in patients by the oral and intravenous route is approximately 9 hours, with a wide inter-subject variability.

Pharmacokinetics in special populations

Renal failure

In patients with severe renal failure, data indicate that pharmacokinetic parameters after a single intravenous dose are generally similar to those in normal subjects.

Hepatic impairment

In patients with hepatic impairment due to neoplastic liver involvement, total plasma clearance of an intravenous dose was approximately halved compared to patients without hepatic involvement. Despite these changes, no dosage adjustment is necessary (see section 4.2).

Elderly patients

In elderly subjects after single intravenous doses, pharmacokinetic parameters were within the range found for non-elderly subjects.

Paediatric population

In children, after single intravenous doses, pharmacokinetics are similar to those in adults when appropriate parameters (volume of distribution, total plasma clearance) are normalized for body weight.

5.3 Preclinical safety data

Preclinical data revealed no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, reproductive toxicity and genotoxicity. Carcinogenicity studies revealed no special hazard for humans when used in the recommended human dose. However, when administered in higher doses and over a prolonged period of time the risk of carcinogenicity cannot be ruled out.

A study in cloned human cardiac ion channels has shown that granisetron has the potential to affect cardiac repolarisation via blockade of HERG potassium channels. Granisetron has been shown to block both sodium and potassium channels, which potentially affects both depolarization and repolarization through prolongation of PR, QRS, and QT intervals. This data helps to clarify the molecular mechanisms by which some of the ECG changes (particularly QT and QRS prolongation) associated with this class of agents occur. However, there is no modification of the cardiac frequency, blood pressure or the ECG trace. If changes do occur, they are generally without clinical significance.

  1. Pharmaceutical particulars

6.1 List of excipients

Sodium chloride

Citric acid monohydrate

Sodium hydroxide (for pH adjustment)

Water for injections

6.2 Incompatibilities

This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.

 

6.3 Shelf life

3 years

The product should be used immediately after opening. For single use only. Discard any remaining portion.

Shelf life after Dilution:

Chemical and physical in-use stability has been demonstrated for 24 hours at 25°C in normal indoor illumination protected from direct sunlight. From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 – 8°C, unless dilution has taken place in controlled and validated aseptic conditions.

6.4 Special precautions for storage

This product does not require any special temperature storage conditions.

Keep the Pre-filled Syringes in the outer carton in order to protect from light.

For storage conditions after dilution of the medicinal product see section 6.3.

6.5 Nature and contents of container

1 ml, 3 ml and 4 ml colourless Pre-filled Syringes.

Pack sizes: 5 x 1 ml, 10 x 1 ml, 5 x 3 ml, 10 x 3 ml, and 5 x 4 ml, 10 x 4ml.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal and other handling

Preparing the infusion

Granisetron can also be diluted in 20 – 50 ml compatible infusion fluid and then given over 5 minutes as an intravenous infusion in any of the following solutions:

0.9 % w/v sodium chloride injection

0.18 % w/v sodium chloride and 4% glucose injection

5 % w/v glucose injection

Hartmann’s solution

1.87 % w/v sodium lactate injection

10% mannitol injection

1.4% w/v sodium hydrogen carbonate injection

2.74% w/v sodium hydrogen carbonate injection

4.2% w/v sodium hydrogen carbonate injection

No other diluents should be used.

Children 2 years of age and older: To prepare the dose of 10 – 40 µg/kg, the appropriate volume is withdrawn and diluted with infusion fluid (as for adults) to a total volume of 10 – 30 ml.

As a general precaution, Granisetron should not be mixed in solution with other drugs

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

  1. Manufactured in India by:
    TAJ PHARMACEUTICALS LTD.
    Mumbai, India
    Unit No. 214.Old Bake House,
    Maharashtra chambers of  Commerce Lane,
    Fort, Mumbai – 400001
    at:Gujarat, INDIA.
    Customer Service and Product Inquiries:
    1-800-TRY-FIRST (1-800-222-434 & 1-800-222-825)
    Monday through Saturday 9:00 a.m. to 7:00 p.m. EST
    E-mail: tajgroup@tajpharma.com

Granisetron Hydrochloride solution for injection USP 1 mg/1ml; 3mg/3ml; 4mg/4ml in Pre-filled Syringe Taj Pharma

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

– Keep this leaflet. You may need to read it again.

– If you have any further questions, ask your doctor, nurse or pharmacist.

– This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.

– If you get any side effects, talk to your doctor, nurse or pharmacist. This includes any possible side effects not listed in this leaflet.

Active substance: Granisetron Hydrochloride Pre-filled Syringe

What is in this leaflet:

  1. What Granisetron Hydrochloride Pre-filled Syringe is and what it is used for
  2. What you need to know before you are given Granisetron Hydrochloride Pre-filled Syringe
  3. How Granisetron Hydrochloride Pre-filled Syringe will be given
  4. Possible side effects
  5. How to store Granisetron Hydrochloride Pre-filled Syringe
  6. Contents of the pack and other information
  7. WHAT GRANISETRON HYDROCHLORIDE PRE-FILLED SYRINGE IS AND WHAT IT IS USED FOR

Granisetron Hydrochloride Pre-filled Syringe contains a medicine called granisetron. This belongs to a group of medicines called ‘5-HT3 receptor antagonists’ or ‘antiemetics’.

Granisetron Hydrochloride Pre-filled Syringe is used to prevent or treat nausea (feeling sick) and vomiting (being sick) caused by other medical treatments, such as chemotherapy or radiotherapy for cancer, and by surgery.

The solution for injection or infusion is for use in adults, adolescents and children from 2 years of age.

  1. WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN GRANISETRON HYDROCHLORIDE PRE-FILLED SYRINGE

Do not use Granisetron Hydrochloride Pre-filled Syringe

– if you are allergic (hypersensitive) to granisetron or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Talk to your doctor, nurse or pharmacist before using Granisetron

Check with your doctor, nurse or pharmacist before using Granisetron Hydrochloride Pre-filled Syringe if you:

– have problems with your bowel movements because of a blockade of your gut (intestines)

– have heart problems, are being treated for cancer with a medicine that is known to damage your heart or have problems with levels of salts, such as potassium, sodium or calcium in your body (electrolyte abnormalities)

– are taking other ‘5-HT3 receptor antagonist’ medicines. These include dolasetron and ondansetron used like Granisetron Hydrochloride Pre-filled Syringe in the treatment and prevention of nausea and vomiting.

Serotonin syndrome is an uncommon but potentially lifethreatening reaction that can occur with granisetron (see section 4). The reaction can occur if you take granisetron

alone but it is more likely to occur if you take granisetron with certain other medicines (in particular fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram, venlafaxine, duloxetine).

Other medicines and Granisetron

Please tell your doctor, nurse or pharmacist if you are taking, have recently taken or might take any other medicines. This is because Granisetron Hydrochloride Pre-filled Syringe can affect the way some medicines work. Also some other medicines can affect the way this injection or infusion works.

In particular, tell your doctor, nurse or pharmacist if you are taking the following medicines:

–  medicines used to treat an irregular heartbeat or other ‘5-HT3 receptor antagonist’ medicines such as dolasetron or ondansetron (see ‘Warnings and precautions’ above)

–  phenobarbital, a medicine used to treat epilepsy.

– SSRIs (selective serotonin reuptake inhibitors) used to treat depression and/or anxiety. Examples are fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram.

– SNRIs (serotonin noradrenaline reuptake inhibitors) used to treat depression and/or anxiety. Examples are venlafaxine, duloxetine.

Pregnancy and breastfeeding

You should not have this injection or infusion if you are pregnant, trying to get pregnant or are breastfeeding, unless your doctor has told you to.

If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor, nurse or pharmacist for advice before taking this medicine.

Driving and using machines

Granisetron Hydrochloride Pre-filled Syringe is not likely to affect your ability to drive or use any tools or machines.

Granisetron Hydrochloride Pre-filled Syringe contains sodium

This medicine contains:

–  a maximum of 27.7 mg (or 1.2 mmol) sodium (main component of cooking/table salt) per 1 ml Pre-filled Syringes.

This is equivalent to 1.4% of the recommended maximum daily dietary intake of sodium for an adult

–  a maximum of 83.1 mg (or 3.6 mmol) sodium (main component of cooking/table salt) per 3 ml Pre-filled Syringes.

This is equivalent to 4.2% of the recommended maximum daily dietary intake of sodium for an adult

  1. HOW GRANISETRON HYDROCHLORIDE PRE-FILLED SYRINGE WILL BE GIVEN

The injection or infusion will be given to you by a doctor or nurse. The dose of Granisetron Hydrochloride Pre-filled Syringe  varies from one patient to another. It depends on your age, weight, and whether you are being given the medicine to prevent, or treat, nausea and vomiting. The doctor will work out how much to give you.

Granisetron Hydrochloride Pre-filled Syringe can be given as an injection or infusion into the veins (intravenous).

Dosage

The usual doses are:

Prevention of feeling or being sick following radio- or chemotherapy

You will be given the injection or infusion before your radio- or chemotherapy starts. The injection or infusion into your veins will take between 30 seconds (injection) and 5 minutes (infusion) and the dose will usually be between 1 and 3 mg. The medicine may be diluted before it is injected.

Treatment of feeling or being sick following radio- or chemotherapy

The injection or infusion will take between 30 seconds (injection) and 5 minutes (infusion) and the dose will usually be between 1 and 3 mg. The medicine may be diluted before it is injected or infused into your veins.

You may be given more injections or infusions to stop

your sickness after the first dose. There will be at least 10 minutes between each dose. The most Granisetron Hydrochloride Pre-filled Syringe you will be given is 9 mg a day.

Combination with steroids

The effect of the injection or infusion may be improved by the use of medicines called adrenocortical steroids. The steroid will be given either as a dose between 8 and 20 mg dexamethasone before your radio- or chemotherapy or as 250 mg methyl-prednisolone, which will be given both before and after your radio- or chemotherapy.

Use in children in the prevention or treatment of feeling or being sick following chemotherapy

Children will be given Granisetron Hydrochloride Pre-filled Syringe by infusions into a vein as described above with the dose depending on the child’s weight. The infusions will be diluted and be given before chemotherapy and will take 5 minutes.

Children will be given a maximum of 2 doses a day, at least 10 minutes apart.

Treatment of feeling or being sick following surgery

The injection into your veins will take between 30 seconds and 5 minutes and the dose will usually be 1 mg. The most Granisetron Hydrochloride Pre-filled Syringe you will be given is 3 mg a day.

Use in children in the prevention or treatment of feeling or being sick following surgery

Children should not be given this injection to treat sickness or the feeling of sickness after surgery.

If you are given more Granisetron Hydrochloride Pre-filled Syringe  than you should

Because the injection or infusion will be given to you by a doctor or nurse, it is unlikely that you will be given too much. However, if you are worried talk to your doctor or nurse.

Symptoms of overdose include mild headaches.

You will be treated depending on your symptoms.

If you have any further questions on the use of this medicine, ask your doctor, nurse or pharmacist.

For information intended for healthcare professionals please see accordant section below.

  1. POSSIBLE SIDE EFFECTS

Like all medicines, this medicine can cause side effects, although not everybody gets them.

If you notice the following problem you must see a doctor straight away:

  • Allergic reactions (anaphylaxis). The signs may include swelling of the throat, face, lips and mouth, difficulty in breathing or swallowing.

Other side effects that may be experienced while taking this medicine are:

Very common (affects more than 1 user in 10):

  • Headache
  • Constipation. Your doctor will monitor your condition.

Common (affects up to 1 in 10 users):

  • Difficulty in sleeping (insomnia)
  • Diarrhoea
  • Changes in how your liver is working shown by blood tests

Uncommon (affects up to 1 in 100 users):

  • Skin rashes or an allergic skin reaction or “nettlerash” or “hives” (urticaria). The signs may include red, raised itchy bumps.
  • Abnormal involuntary movements, such as shaking, muscle rigidity and muscle contractions
  • Changes in the heartbeat (rhythm) and changes seen on ECG readings (electrical recordings of the heart)

Serotonin Syndrome. The signs may include

diarrhoea, nausea, vomiting, high temperature and blood pressure, excessive sweating and rapid heartbeat, agitation, confusion, hallucination, shivering, muscles shakes, jerks or stiffness, loss of coordination and restlessness.

 

Reporting of side effects.

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects. By reporting side effects you can help provide more information on the safety of this medicine.

  1. HOW TO STORE GRANISETRON HYDROCHLORIDE PRE-FILLED SYRINGE

Keep this medicine out of the sight and reach of children.

This product does not require any special temperature storage conditions.

Keep the Pre-filled Syringes in the outer carton in order to protect from light.

Do not use this medicine after the expiry date which is stated on the Pre-filled Syringes label and the outer carton after “EXP.”. The expiry date refers to the last day of that month.

Do not use this medicine if you notice the solution is not clear or free from particles.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures willhelp to protect the environment.

  1. CONTENTS OF THE PACK AND OTHER INFORMATION

What Granisetron Hydrochloride Pre-filled Syringe contains

The active substance is granisetron hydrochloride

Each 1 ml Pre-filled Syringes contains a total content of 1 mg granisetron as the hydrochloride in 1 ml of a sterile solution.

Each 3 ml Pre-filled Syringes contains a total content of 3 mg granisetron as the hydrochloride in 3 ml of a sterile solution.

Each 4 ml Pre-filled Syringes contains a total content of 4 mg granisetron as the hydrochloride in 4 ml of a sterile solution.

The other ingredients are sodium chloride, citric acid monohydrate, sodium hydroxide and water for injections.

What Granisetron Hydrochloride Pre-filled Syringe looks like and contents of the pack

Granisetron Hydrochloride Pre-filled Syringe is a clear, colourless concentrate for solution for injection or infusion.

Pack size:

Granisetron Hydrochloride Pre-filled Syringe is available in packs of five or ten Pre-filled Syringes filled with 1 ml, 3 ml or
4 ml of the solution.

Not all pack sizes may be marketed.

7. Manufactured in India by:
TAJ PHARMACEUTICALS LTD.
Mumbai, India
Unit No. 214.Old Bake House,
Maharashtra chambers of  Commerce Lane,
Fort, Mumbai – 400001
at:Gujarat, INDIA.
Customer Service and Product Inquiries:
1-800-TRY-FIRST (1-800-222-434 & 1-800-222-825)
Monday through Saturday 9:00 a.m. to 7:00 p.m. EST
E-mail: tajgroup@tajpharma.com